公开(公告)号：US20210000782A1

公开(公告)日：2021-01-07

申请号：US16980429

申请日：2019-01-14

申请人： NANJING UNIVERSITY OF CHINESE MEDICINE

发明人： Xu SHEN ,  Jiaying WANG ,  Xiaoju XU

IPC分类号： A61K31/216 ,  A61P25/02

摘要： The present invention relates to application of drofenine or a pharmaceutically acceptable salt thereof in the preparation of medicine for treating peripheral neuron axonal injury and peripheral related neuropathy. The drofenine or the pharmaceutically acceptable salt thereof has a significant effect on promoting growth of peripheral sensory neurites, and can relieve symptoms of low nerve conduction velocity and sensation loss of STZ-induced type I diabetic mice and db/db type II diabetic mice, thereby treating diabetic peripheral neuropathy.

公开(公告)号：US20230086152A1

公开(公告)日：2023-03-23

申请号：US17998792

申请日：2021-12-14

申请人： NANJING UNIVERSITY OF CHINESE MEDICINE

发明人： Xu SHEN ,  Jiaying WANG ,  Yujie HUANG ,  Jian LU

IPC分类号： A61K31/4465 ,  A61P25/28

摘要： The present disclosure discloses a new use of desloratadine (DLT) and pharmaceutically acceptable salts thereof in preparing a drug for treating a neurodegenerative disease related to motor dysfunction. The present disclosure shows, through a large number of experimental tests, that desloratadine and the pharmaceutically acceptable salts thereof can improve the state of motor dysfunction in an SOD1-G93A model mouse in the behavioral experimental tests of Rotarod experimental test, gait monitoring experimental test and cage experimental test, and that desloratadine and the pharmaceutically acceptable salts thereof can effectively delay the onset time and prolong the survival cycle of the SOD1-G93A model mouse, and therefore, desloratadine and the pharmaceutically acceptable salts thereof can be used to treat neurodegenerative diseases related to motor dysfunction, including amyotrophic lateral sclerosis.